Pfizer has licensed access to KineMed’s platform technology to discover, develop, and potentially commercialize new kinetic biomarkers in multiple therapy areas, KineMed said today.

The value of the collaboration was not disclosed, and the therapy areas were described only as “various fields of unmet medical need.”

KineMed did disclose it will receive an upfront payment, plus funding for R&D costs associated with the targets, to be selected by Pfizer. KineMed also said it is eligible to receive payments tied to achieving development and regulatory milestones.

The companies agreed to work together toward discovery research of novel biomarkers, with Pfizer overseeing development and potential commercialization of any novel biomarkers or companion diagnostics for the targets.

KineMed aims to create a pipeline of treatments in muscle-wasting and fibrotic diseases. The pipeline today is focused on Phase II trials with synthetic Ghrelin to address chronic kidney disease and muscle wasting among elderly people. KineMed says it intends to clinically advance multiple drug candidates—whether in-licensed, partnered, or acquired—for out-licensing after the Phase II trials.

According to KineMed, its kinetic biomarkers are designed to provide rates of change of key proteins involved with therapeutic efficacy and target engagement, using mass spectroscopy and stable isotope labeling of protein turnover.

“We believe our kinetic biomarker platform provides real advantages over other approaches to biomarker discovery in de-risking and advancing medicines development, and this collaboration with Pfizer is an important step toward helping us realize the full potential of this technology,” KineMed president Patrick Doyle said in a statement.